A phase I study of docetaxel plus synthetic lycopene in metastatic prostate cancer patients

CONCLUSIONS: The combination of docetaxel/ADT and synthetic lycopene has low toxicity and favourable pharmacokinetics. The effects of lycopene on biomarkers provide additional support for the toxicity-dependent MTD definition.HIGHLIGHTS: The maximum tolerated dose was identified as 150 mg/day of lycopene in combination with docetaxel/ADT for the treatment of metastatic prostate cancer patients. Small increases in plasma exposure to docetaxel were observed with lycopene co-administration. Mechanistically significant effects were seen on angiogenesis and insulin-like growth factor 1 signalling by lycopene co-administration with docetaxel/ADT.PMID:38515274 | PMC:PMC10958125 | DOI:10.1002/ctm2.1627
Source: Methods of Information in Medicine - Category: Information Technology Authors: Source Type: research